Standout Papers

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, singl... 2019 2026 2021 2023 358
  1. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (2019)
    Kathleen N. Moore, Angeles Alvarez Secord et al. The Lancet Oncology

Immediate Impact

11 from Science/Nature 53 standout
Sub-graph 1 of 24

Citing Papers

Interferon- γ and infectious diseases: Lessons and prospects
2024 StandoutScience
Towards targeting the breast cancer immune microenvironment
2024 Standout
1 intermediate paper

Works of Kaiming Sun being referenced

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
2019
The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes
2009

Author Peers

Author Last Decade Papers Cites
Kaiming Sun 435 657 101 261 19 1.0k
Mark G. Cadungog 527 625 100 520 17 1.3k
Alexandra S. Zimmer 350 786 325 179 24 1.1k
Mei‐Kuang Chen 516 882 184 337 24 1.2k
Christin Whalen 480 772 145 152 22 1.1k
Denarda Dangaj Laniti 356 671 74 527 29 1.1k
Yang Peng 880 771 138 278 25 1.3k
D Katsaros 375 516 71 331 15 1000
Agnes S. Lo 402 492 106 581 27 1.4k
Katarzyna Kluzek 791 806 140 83 14 1.1k
Eva Schut 861 695 91 196 15 1.2k

All Works

Loading papers...

Rankless by CCL
2026